<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069860</url>
  </required_header>
  <id_info>
    <org_study_id>12k002</org_study_id>
    <secondary_id>CIV-13-11-011681</secondary_id>
    <secondary_id>37790</secondary_id>
    <nct_id>NCT02069860</nct_id>
  </id_info>
  <brief_title>BONE ANCHORED PORT for Hemodialysis Treatment</brief_title>
  <acronym>BAP</acronym>
  <official_title>Bone Anchored Port - a Novel Vascular Access for Hemodialysis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cendres+Métaux</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cendres+Métaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Bone Anchored Port System (BAP) will be implanted in the mastoid bone behind the ear,&#xD;
      connected with a double lumen central venous catheter inserted in the jugular vein, and will&#xD;
      be used in conjunction with an adapter as a permanent vascular access for hemodialysis&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVE The objective of the clinical investigation is to demonstrate feasibility&#xD;
      regarding safety, efficiency and clinical performance of the BAP as a permanent access for&#xD;
      chronic haemodialysis therapy in patients with renal failure to reach the certificate&#xD;
      European (CE) mark and conduct a post market follow-up study.&#xD;
&#xD;
      PRIMARY ENDPOINT&#xD;
&#xD;
      1) Device survival probability after one year (product - limit estimator of Kaplan-Meier&#xD;
      Analysis). An event is the primary failure of BAP, defined by necessity to remove the device:&#xD;
      for any medical reason (e.g. infections at wound or mastoid, thrombosis, and severe patient&#xD;
      discomfort)&#xD;
&#xD;
      SECONDARY ENDPOINTS&#xD;
&#xD;
        1. Performance - Implantation and primary healing process&#xD;
&#xD;
             -  Failure to implant a device due to procedural complications or unforeseen&#xD;
                anatomical reasons, except for intra-operatively detected exclusion criteria&#xD;
&#xD;
             -  Successful attempt on the site contralateral to the planned side&#xD;
&#xD;
             -  Duration of the implantation procedure measured from incision to final suture&#xD;
&#xD;
             -  Duration of hospitalization before implantation / after implantation&#xD;
&#xD;
             -  Time from implantation to first use for haemodialysis&#xD;
&#xD;
             -  Rate of patients with complications stratified by&#xD;
&#xD;
                  -  Dura mater exposed / injured&#xD;
&#xD;
                  -  Blood sinus injured&#xD;
&#xD;
                  -  Injury of facial nerve&#xD;
&#xD;
                  -  Carotid artery puncture&#xD;
&#xD;
                  -  Central vein perforation&#xD;
&#xD;
                  -  Bleeding, defined as requirement for blood products&#xD;
&#xD;
                  -  Pneumothorax&#xD;
&#xD;
                  -  Hematothorax&#xD;
&#xD;
             -  Initial healing and stabilization of BAP, Infections at implantation site&#xD;
&#xD;
             -  Septicaemias with no other source of infection than surgical-procedures impairment&#xD;
                for mechanical reasons&#xD;
&#xD;
        2. Performance - removal of catheter&#xD;
&#xD;
             -  Failure to provide a blood flow ≥200ml/min for more than 2 consecutive weeks&#xD;
&#xD;
             -  Catheter related and untreatable infection&#xD;
&#xD;
             -  Surgical or interventional (Seldinger technique) procedure&#xD;
&#xD;
             -  Persistent recirculation higher than 15%&#xD;
&#xD;
        3. Performance - Dialysis use&#xD;
&#xD;
             -  Average blood flow rate&#xD;
&#xD;
             -  Average venous pressure&#xD;
&#xD;
             -  Average arterial pressure&#xD;
&#xD;
             -  Recirculation&#xD;
&#xD;
             -  Volume-corrected clearance (Kt/V)&#xD;
&#xD;
             -  Access thrombosis reversible by non-surgical means&#xD;
&#xD;
             -  Infections of any kind&#xD;
&#xD;
                  -  in anatomical structures around implant&#xD;
&#xD;
                  -  remote infections possibly related to the BAP&#xD;
&#xD;
                  -  bacteriemia/septicemia&#xD;
&#xD;
        4. Design Validation&#xD;
&#xD;
             -  Questionnaire for the implantation surgeon&#xD;
&#xD;
             -  Questionnaire for the dialysis staff&#xD;
&#xD;
             -  Questionnaire for patients&#xD;
&#xD;
             -  Quality of Life (QoL) Questionnaire (EQ-5D)&#xD;
&#xD;
             -  Questionnaire for change / removal of catheter&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device survival probability after one year</measure>
    <time_frame>up to 12 months after Study start</time_frame>
    <description>An event is the primary failure of BAP, defined by necessity to remove the device for any medical reason (e.g. infections at wound or mastoid, thrombosis, and severe patient discomfort).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance - Implantation and primary healing process</measure>
    <time_frame>up to 18 months after Study start</time_frame>
    <description>Failure to implant a device due to procedural complications or unforeseen anatomical reasons, except for intra-operatively detected exclusion criteria&#xD;
Successful attempt on the site contralateral to the planned side&#xD;
Duration of the implantation procedure measured from incision to final suture&#xD;
Duration of hospitalization before implantation / after implantation&#xD;
Time from implantation to first use for haemodialysis&#xD;
Rate of patients with complications stratified by&#xD;
Dura mater exposed / injured&#xD;
Blood sinus injured&#xD;
Injury of facial nerve&#xD;
Carotid artery puncture&#xD;
Central vein perforation&#xD;
Bleeding, defined as requirement for blood products&#xD;
Pneumothorax&#xD;
Hematothorax&#xD;
Initial healing and stabilization of BAP, Infections at implantation site&#xD;
Septicaemias with no other source of infection than surgical-procedures impairment for mechanical reasons</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Performance - removal of catheter</measure>
    <time_frame>up to 18 months after Study start</time_frame>
    <description>Failure to provide a blood flow ≥200ml/min for more than 2 consecutive weeks&#xD;
Catheter related and untreatable infection&#xD;
Surgical or interventional (Seldinger technique) procedure&#xD;
Persistent recirculation higher than 15%</description>
  </other_outcome>
  <other_outcome>
    <measure>Performance - Dialysis use</measure>
    <time_frame>up to 18 months after Study start</time_frame>
    <description>Average blood flow rate&#xD;
Average venous pressure&#xD;
Average arterial pressure&#xD;
Recirculation&#xD;
Volume-corrected clearance (Kt/V)&#xD;
Access thrombosis reversible by non-surgical means&#xD;
Infections of any kind&#xD;
in anatomical structures around implant (skin: Holgers' Classification System)&#xD;
in port&#xD;
in catheter&#xD;
remote infections possibly related to the BAP&#xD;
bacteriemia/septicemia</description>
  </other_outcome>
  <other_outcome>
    <measure>Design Validation</measure>
    <time_frame>up to 18 months after Study start</time_frame>
    <description>Usability implantation tools &amp; procedure&#xD;
Assessment dialysis staff / Problems during dialysis&#xD;
Daily life with BAP&#xD;
Patient health status (Questionnaire EQ-5D)&#xD;
Feasibility of catheter change / removal</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>End-Stage Renal Disease Requiring Haemodialysis</condition>
  <condition>Hemodialysis Access Failure (Disorder)</condition>
  <arm_group>
    <arm_group_label>Access for heamodialysis treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Bone Anchored Port System (BAP) will be implanted in the mastoid bone behind the ear, connected with a double lumen central venous catheter inserted in the jugular vein, and will be used in conjunction with an adapter as a permanent vascular access for hemodialysis treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bone Anchored Port System (BAP)</intervention_name>
    <description>The port body will be implanted onto the petrous bone and a sealing cap, a twofold valve system and a catheter are connected to the port body. The catheter is tunneled under the skin, enters the internal jugular vein and ends in the right atrium of the heart. The novelty of the access lies in its location (retro auricular on petrous bone) and its bone fixation.</description>
    <arm_group_label>Access for heamodialysis treatment</arm_group_label>
    <other_name>Retroauricular anchored devices</other_name>
    <other_name>Permanent central venous vascular access devices</other_name>
    <other_name>Tunneled catheters</other_name>
    <other_name>BAHA and Jarvik 2000 pedestal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Indication for a permanent haemodialysis access&#xD;
&#xD;
          -  Impossibility to construct or revise an AC-Fistula&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Written, informed consent.&#xD;
&#xD;
          -  Availability of vascular imaging of the jugular vein at the implantation site with no&#xD;
             contraindication for a jugular vein catheter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical contraindications for the implantation of a BAP including:&#xD;
&#xD;
               -  known intolerance to any of the BAP materials&#xD;
&#xD;
               -  ongoing infections e.g.&#xD;
&#xD;
                    -  mastoiditis / otitis media&#xD;
&#xD;
                    -  skin infection in the area of presumed implantation-site&#xD;
&#xD;
                    -  generalized acute and chronic infections&#xD;
&#xD;
               -  severe skin lesions (e.g. dermatitis, psoriasis) in the area of the presumed&#xD;
                  implantation site&#xD;
&#xD;
               -  previous surgery at the petrous bone&#xD;
&#xD;
               -  deafness&#xD;
&#xD;
               -  known significant bleeding disorder&#xD;
&#xD;
               -  known thrombophilia&#xD;
&#xD;
          2. Life expectancy less than 1 year from the time of enrolment in the study.&#xD;
&#xD;
          3. Expected transplantation within the intended study duration (i.e. known living donor).&#xD;
&#xD;
          4. Pregnancy or breast feeding.&#xD;
&#xD;
          5. Women of childbearing potential without appropriate contraceptive method.&#xD;
&#xD;
          6. Patient known to be HIV, hepatitis C or hepatitis B antigen positive.&#xD;
&#xD;
          7. Any form of substance abuse, psychiatric disorder or condition which, in the opinion&#xD;
             of the investigator may complicate communication with the investigator.&#xD;
&#xD;
          8. Participation in another clinical study (medicinal, medical device) within the last 30&#xD;
             days.&#xD;
&#xD;
          9. Multiple participation of one subject in this clinical investigation.&#xD;
&#xD;
         10. Inability to understand German and to give written informed consent.&#xD;
&#xD;
         11. Patients suffering from epilepsy, addiction or other condition resulting in a higher&#xD;
             risk of falling.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uehlinger Dominik, Prof. Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Insel hospital, Bern, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 11, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Anchored Port</keyword>
  <keyword>Haemodialysis</keyword>
  <keyword>Mastoid bone</keyword>
  <keyword>Nephrology</keyword>
  <keyword>Retroauricular anchored devices</keyword>
  <keyword>Permanent central venous vascular access</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Vascular Access for Haemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

